Skip to main content
. 2024 Oct 10;8(11):e0561. doi: 10.1097/HC9.0000000000000561

FIGURE 2.

FIGURE 2

Illustration of the process from steatotic liver disease to a healthy liver using GLP-1 receptor agonists: GLP-1 receptor agonists inhibit risk factors (insulin resistance and excessive alcohol, obesity), promoting reduced hepatic steatosis and inflammation. Abbreviations: GLP-1, glucagon-like peptide 1; SLD, steatotic liver disease.